US EditionNaviFUS Corp. Leverages Taiwan's Advanced Chip Technology to Lead Non-Invasive Precision Medicine for Brain Disorders
- NaviFUS Corp. Is advancing non-invasive treatments for brain disorders using ultrasound technology, surpassing traditional devices' capabilities, driven by Taiwan's chip technology.
- The company completed a Phase II clinical trial in Taiwan, achieving a 66.7% progression-free survival rate at six months for patients with recurrent glioblastoma.
- NaviFUS's system also offers significant reductions in seizure frequency for drug-resistant epilepsy, with ongoing Phase II trials in Taiwan and pilot studies in Australia and the United States.
- Taiwan's government prioritizes the biomedical industry, with Chairman Jen Chen noting a focus on internationalizing smart healthcare solutions to elevate the country's global standing.
Insights by Ground AI
Does this summary seem wrong?
50 Articles
50 Articles
All
Left
4
Center
9
Right
3
Coverage Details
Total News Sources50
Leaning Left4Leaning Right3Center9Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 25%
C 56%
R 19%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
